Ablynx NV-Product Pipeline Review-2015

Ablynx NV-Product Pipeline Review-2015

  • Products Id :- GMDHC06996CDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ablynx NV-Product Pipeline Review-2015


Global Markets Direct's, 'Ablynx NV-Product Pipeline Review-2015', provides an overview of the Ablynx NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ablynx NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Ablynx NV including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Ablynx NV's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Ablynx NV's pipeline products

Reasons To Buy

Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Ablynx NV in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Ablynx NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Ablynx NV and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ablynx NV

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Ablynx NV and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ablynx NV Snapshot 6

Ablynx NV Overview 6

Key Information 6

Key Facts 6

Ablynx NV-Research and Development Overview 7

Key Therapeutic Areas 7

Ablynx NV-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Ablynx NV-Pipeline Products Glance 16

Ablynx NV-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Ablynx NV-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Ablynx NV-Drug Profiles 20

ALX-0061 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ALX-0171 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

caplacizumab 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ozoralizumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ALX-0141 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody to Target c-Met for Multiple Myeloma 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

TLC-520 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibodies for Inflammation, Immunology and Infections 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibodies for Oncology, Immunology and Neurology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Monoclonal Antibody 1 for Inflammation and Immunology 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody 1 for Oncology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody 1 for Pulmonary Disease 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody 2 for Inflammation and Immunology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody 2 for Oncology 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Monoclonal Antibody 2 for Pulmonary Disease 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Monoclonal Antibody 3 for Inflammation and Immunology 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Monoclonal Antibody for Immunology 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Monoclonal Antibody for Ocular Diseases 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Monoclonal Antibody for Pulmonary Diseases 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Ablynx NV-Pipeline Analysis 44

Ablynx NV-Pipeline Products by Target 44

Ablynx NV-Pipeline Products by Route of Administration 45

Ablynx NV-Pipeline Products by Molecule Type 46

Ablynx NV-Pipeline Products by Mechanism of Action 47

Ablynx NV-Recent Pipeline Updates 48

Ablynx NV-Dormant Projects 56

Ablynx NV-Dormant Projects 56

Ablynx NV-Discontinued Pipeline Products 57

Discontinued Pipeline Product Profiles 57

ALX-0962 57

BI-1034020 57

Ablynx NV-Company Statement 58

Ablynx NV-Locations And Subsidiaries 61

Head Office 61

Other Locations & Subsidiaries 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

Ablynx NV, Key Information 6

Ablynx NV, Key Facts 6

Ablynx NV-Pipeline by Indication, 2015 8

Ablynx NV-Pipeline by Stage of Development, 2015 10

Ablynx NV-Monotherapy Products in Pipeline, 2015 11

Ablynx NV-Partnered Products in Pipeline, 2015 12

Ablynx NV-Partnered Products/ Combination Treatment Modalities, 2015 13

Ablynx NV-Out-Licensed Products in Pipeline, 2015 14

Ablynx NV-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

Ablynx NV-Phase II, 2015 16

Ablynx NV-Phase I, 2015 17

Ablynx NV-Preclinical, 2015 18

Ablynx NV-Discovery, 2015 19

Ablynx NV-Pipeline by Target, 2015 44

Ablynx NV-Pipeline by Route of Administration, 2015 45

Ablynx NV-Pipeline by Molecule Type, 2015 46

Ablynx NV-Pipeline Products by Mechanism of Action, 2015 47

Ablynx NV-Recent Pipeline Updates, 2015 48

Ablynx NV-Dormant Developmental Projects,2015 56

Ablynx NV-Discontinued Pipeline Products, 2015 57

Ablynx NV, Subsidiaries 61

List of Figures

Ablynx NV-Pipeline by Top 10 Indication, 2015 8

Ablynx NV-Pipeline by Stage of Development, 2015 10

Ablynx NV-Monotherapy Products in Pipeline, 2015 11

Ablynx NV-Partnered Products in Pipeline, 2015 12

Ablynx NV-Out-Licensed Products in Pipeline, 2015 14

Ablynx NV-Pipeline by Top 10 Target, 2015 44

Ablynx NV-Pipeline by Top 10 Route of Administration, 2015 45

Ablynx NV-Pipeline by Top 10 Molecule Type, 2015 46

Ablynx NV-Pipeline Products by Top 10 Mechanism of Action, 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Ablynx NV; Ablynx NV - Key Therapeutics; Ablynx NV - Pipeline Overview and Promising Molecules; Ablynx NV - News; Ablynx NV - Latest Updates; Ablynx NV - Pipeline; Ablynx NV - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 100395
Site License
USD 3000 INR 200790
Corporate User License
USD 4500 INR 301185



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com